Research programme: vascular disrupting agents - Madrigal Pharmaceuticals

Drug Profile

Research programme: vascular disrupting agents - Madrigal Pharmaceuticals

Alternative Names: STA-9584

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator Synta Pharmaceuticals
  • Developer Madrigal Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 22 Jul 2016 Madrigal Pharmaceuticals merged with Synta Pharmaceuticals and the combined company is now called Madrigal Pharmaceuticals
  • 24 Nov 2010 Preclinical development is ongoing in USA
  • 04 Sep 2007 Preclinical trials in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top